- Some frightening stats about Alzheimer’s disease…
- … and a new study shows a connection to artery health
- Ray Blanco: A biotech visionary bucks conventional wisdom
- How Apple juiced earnings to bounce back from December lows
- Will Boeing drag the Dow down with it?
- Business owners’ — meh — optimism
- The honest-to-God inflation rate (brace yourselves)
- A case of mistaken identity — hipster edition
When Roger was 71 years old, his wife noticed he was no longer interested in lifelong hobbies like golf and playing cards. Instead, Roger spent long stretches sitting in front of the television and, contrary to previous habits, sleeping up to 13 hours per night.
His wife encouraged him to visit his primary care physician, who prescribed an antidepressant; when that didn’t help, Roger’s doctor ordered a psychiatric evaluation.
To the psychiatrist examining him, Roger admitted he was less energetic and outgoing since he’d retired four years earlier but said he didn’t feel markedly sad. Roger’s take? He’d simply retired too early.
As for the exam, Roger was able to repeat a complex sentence verbatim, calculate three out of five math problems correctly and recall the year… but he couldn’t remember the month or day of the week.
When Roger completed the full evaluation, he was given the diagnosis one person in the U.S. is given every 65 seconds — Alzheimer’s disease.
A few things: If only Roger’s primary care physician hadn’t rushed to judgment…
- According to the Alzheimer’s Association, only 16% of older Americans receive cognitive assessments during regular health checkups
- Taking into account 1 in 3 seniors dies with Alzheimer’s or dementia, cognitive assessments should be routine
- Not only that, but Roger’s health history should have raised red flags: He had high blood pressure and high cholesterol — and both contribute to a newfound risk factor…
According to a study published in the Journal of Alzheimer’s Disease, “Arterial stiffness is a good proxy for predicting who will go on to develop dementia.”
Arterial stiffening occurs when the layers of the artery walls are damaged by things like inflammation, high blood pressure and high cholesterol; as a result — over time — arteries become less elastic and less able to regulate proper blood flow.
Source: Ask the Scientists
“As [arteries stiffen], their ability to cushion the pumping of blood from the heart is diminished, and that transmits increased pulsing force to the brain, which contributes to silent brain damage that increases dementia risk,” says the study’s senior author Rachel Mackey, Ph.D., assistant professor of epidemiology at the University of Pittsburgh.
She continues: “Although arterial stiffness is associated with markers of silent, or subclinical, brain damage and cognitive decline, until now, it was not clear that arterial stiffness was associated with the risk of dementia.”
The 15-year study followed 356 older adults, none of whom had dementia at the study’s outset. By the end of the study, participants diagnosed with arterial stiffness were 60% more likely to develop dementia, including Alzheimer’s disease.
That’s clinically significant… but there’s a silver lining.
The study says: “Arterial stiffening can be reduced by antihypertensive medication and perhaps also healthy lifestyle changes such as exercise.
“For example, this study showed that exercise at an average age of 73 was associated with lower [risk of arterial stiffness] five years later.”
“What’s exciting to think about,” says Dr. Mackey, “is that the strong association of arterial stiffness to dementia in old age suggests that even at age 70 or 80, we might still be able to delay or prevent the onset of dementia.”
[Coincidentally, vitamins K, D and omega-3 fatty acids all promote artery elasticity. As for exercise, a recent study published in JAMA: The Journal of the American Medical Association showed “increasing physical activity during midlife was associated with 32–35% lower risk for mortality.”]
The hard truth is already “more than 5 million Americans suffer from Alzheimer’s disease,” says our biotechnology expert Ray Blanco, “and millions more will be diagnosed in the years to come.”
Frightening as it is, “there’s a good chance you or someone you love is already developing the disease,” he continues. “The number of people with Alzheimer’s is growing by double-digit percentages every year.”
Until now, we’ve only talked about Americans like Roger who suffer from Alzheimer’s; worldwide, the outlook’s even more depressing….
More depressing still? The medical and pharmaceutical communities don’t have an answer for this worldwide scourge. “Between 2002 and 2012, there were 413 Alzheimer’s clinical trials testing 244 different drugs,” Ray says.
The outcome: Out of 10 years of research and testing, only one drug was approved by the FDA. And at best it only masks the symptoms of Alzheimer’s, buying sufferers a few precious months.
Now, a doctor and researcher — a recipient of the 2018 Flagship Pioneering Leader Award — is bucking conventional wisdom about the root cause of Alzheimer’s disease.
For years, neuroscientists have concentrated on the proliferation of amyloid plaques on the brains of Alzheimer’s patients. Theoretically, they thought, if you combat the buildup of amyloid proteins, you cure Alzheimer’s disease.
But what if that’s not the root cause of Alzheimer’s? One doctor asked the question — and offered a dissenting opinion.
According to his research, Alzheimer’s disease is more like an autoimmune disease, with a protein called TREM2 attacking healthy brain tissue.
“A TREM2 protein… clears out harmful buildup inside the brain,” Ray says. “This is a completely normal and beneficial part of your brain’s natural immune system.”
With an aging brain — along with other risk factors like arterial stiffness — the TREM2 protein can mutate and “rampant TREM2 proteins kill one healthy brain cell after another,” says Ray.
“Back-to-back papers from The New England Journal of Medicine show that if TREM2 proteins are out of control in your body, your chances of developing Alzheimer’s skyrocket by 200%!
“But this doctor is taking those findings a step further — creating a treatment that specifically targets the true ‘bad actor’ in Alzheimer’s disease,” Ray says.
“Its laserlike focus could mean effectively treating Alzheimer’s.” A cure for Alzheimer’s? The breakthrough of the 21st century.
[Ed. note: Ray’s convinced the gains from this one Alzheimer’s biotech stock will tower over his other stock recommendations.
And Ray’s no stranger to delivering triple-digit gains to his readers…
- A high-tech lens and imaging stock gained 7.4 times the ROI in less than 6 months or — put another way — enough to turn every $5,000 into $37,000
- How about cancer-therapy company OncoSec? Ray’s readers had the chance to walk away with 347% gains in just 23 months
- Then in September, readers who invested in a Huntington’s disease therapy at $11.22 per share closed out at $42.43 per share. Almost quadrupled in 11 months!
If you need more convincing, insiders bought up 11.8 million shares of this Alzheimer’s stock in a single day… Just one more reason Ray believes shares of this company are poised to absolutely skyrocket.
And TOMORROW, March 13, is the day to circle on your calendar…
Ray says: “This might be the biggest — and most profitable — recommendation I’ve ever made.”
Click here to find out how you can cash in on this amazing discovery… but you have to act fast.]
“Tech breakouts lit up Wall Street on Monday as the major averages shook off last week’s sluggish performance,” says Agora analyst Greg Guenthner.
“The Nasdaq Composite led the way with a gain of more than 2%, while the S&P 500 jumped almost 1.5% before the closing bell.”
Specifically, Greg takes a look at Apple’s impressive bounce back from December’s doldrums; Apple played Wall Street’s favorite game: lower expectations… and then beat them.
Apropos of juking the stats, Apple experienced “a post-earnings rally in late January after it beat estimates by just a penny.” Yep, that’s all it took to erase fears about flagging iPhone sales and Apple’s scramble to crack the code on the Chinese market.
“It worked,” says Greg. “Apple’s 6% jump sparked what has become an impressive move off its December lows.”
Looking at the tech-heavy Nasdaq Index today, it’s added 50 points to 7,608. The S&P 500’s also in the green, up 14 points to 2,797.
The Dow’s a different story: The Big Board’s down about 70 points to 2,554… It could be worse considering the global drama surrounding Boeing.
Following the plane crash in Ethiopia on Sunday, Boeing’s shares trimmed losses to 5%, or $22 per share, yesterday.
The concern centers on the Boeing 737 Max 8 aircraft that’s been involved in two plane crashes in six months. Now countries across the globe are grounding the planes, most notably China, the U.K. and the EU.
Will the U.S. ground the planes? So far, Southwest and American Airlines have publicly endorsed the Boeing 737 Max 8.
Boeing shares continue to fall today, down another 7%; since Boeing is the blue chippiest Dow stock, it holds sway over the entire index.
We’ll see how things play out with Boeing…
Turning to February’s NFIB Small Business Optimism Index…
The number shows a modest improvement over January: The index rose just half a point to 101.7. The end of the government shutdown is a plus; on the flip side, good help is still hard to find.
“Small business owners are thankful to have the government shutdown in the rearview mirror but need more certainty about the future,” says NFIB president and CEO Juanita D. Duggan. This despite a five-point gain in those who expect the economy to improve… hmm.
Asked about their single-most important problem, “quality of labor” is far in front — again, good people are hard to find — and it’s been the top category for about a year now.
“U.S. Consumer Prices Rise for the First Time in Four Months,” says a headline at CNBC. Again… a “modest” gain, CNBC says, “resulting in the smallest annual gain in nearly 2½ years.”
The Labor Department reports today its consumer price index (CPI) increased 0.2% for the month of February — this mostly due to rising costs of food, gas and rent. Prior to February, the CPI had been flat for three months straight.
We turn to ShadowStats for an unflinching look at inflation: While the Labor Department reports a 1.5% year-over-year rate (as Dave likes to say, any resemblance to your own cost of living is purely coincidental), the real-world inflation rate stands at 9.22%. That’s the rate the wonks would have calculated 40 years ago… when they were honest?
At any rate (heh), there ain’t no pressure for the Fed to resume raising rates at this juncture — nothing in the numbers should change Jerome Powell’s newfound dovish religion.
Twist ending: A man threatens to sue an MIT journal for using his image for an article about “the hipster effect”…
And — in a case of hipsters not always loving irony — the pic turned out to be a Getty stock image instead of a pic of his bearded, beanied likeness.
Which completely proved the point of the study reviewed by the MIT technology journal: Why do “nonconformists” all end up looking alike? There you have it… the hipster effect.
When the hipster in question saw the publication, he shot off a strongly worded letter to the MIT journal editor, saying: “Your lack of basic journalistic ethics in both the manner in which you ‘reported’ this uncredited nonsense and the slanderous, unnecessary use of my picture without permission demands a response, and I am, of course, pursuing legal action.”
Oooh… he’s an angry hipster.
The editor went to great lengths to ensure the publication had used the image fair and square; he even reached out to Getty images. When Getty confirmed the model didn’t have the same name as the “legal eagle” letter writer, Mr. Hipster backed off, saying: “Oh, I guess you’re right, it’s not [me].”
The 5 Min. Forecast
P.S. Urgent opportunity by tomorrow: Company insiders are doubling down after extraordinary “neuro-tech” breakthrough…
Shares of a tiny, unknown startup on the West Coast could be about to skyrocket.
Need proof? Company insiders have gobbled up 11,843,747 shares of the company’s stock… in a single day.
Whatever they know, the message is clear. Something’s happening — and this one looks like it’s about to make a lot of people very rich.
“It may be easy to hate Wall Street banks, but there’s no question they’re profitable,” Zach Scheidt says. “Why not tap into those profits for yourself?” Read More
“The COVID-19 crisis has exposed our dependence on offshore-made drugs… and raised questions about their availability,” Ray Blanco says. Read More
Because of physical gold’s scarcity, precious metals dealers are able to tack on an average commission of 15%. “Take it or leave it,” says Jim Rickards. Read More
We approach the vaccine passport question from our business-and-commerce perspective… still mindful of what it means to live in a free country. Read More
“Why are higher interest rates so damaging for tech stocks?” a reader asks our income specialist Zach Scheidt. Read More
“The Biden administration has chosen the most economically harmful method of financing infrastructure spending,” says one expert as The 5 pulls apart massive federal spending bills, both old and new Read More
And to think, one year ago the “reopening trade” wasn’t even a thing. Today? You can’t get away from the headlines plastered across financial media… Read More
“Over the course of American history, building infrastructure has had a powerful economic impact,” says Nomi Prins. Read More
Rep. Alexandria Ocasio-Cortez (D-New York) quickly became the face of a leftist faction in the House known as the democratic socialists. That was then, this is now… Read More
The events at hedge fund Archegos Capital Management might not be a “black swan,” but in pockets of the market, there’s an awful lot of gray out there today… Read More